Gout Refractory News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SEL-212 Shows Significant Response Rates, sUA Reductions in Patients with Gout

Investigators believe targeted immunomodulation with SEL-212 may have the potential to introduce a new uricase-based therapy for patients with gout refractory to conventional treatment.

United statesSan diegoHerbert barafGeorge washington universityAmerican college of rheumatologyBone researchNational institute of arthritisNational instituteSkin diseasesGout refractoryConventional treatmentPrimary outcomesTwo randomizedDouble blindMulticenter phaseAmerican college

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (2)

75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of.

United statesCarsten brunnAnders ullmanThomas kudsk larsenheadSelecta biosciencesGuido oelkersPeter traberPrnewswire selecta biosciences incSobi investor relations teamExchange commissionCompany immSelecta biosciences incHead of research developmentChief medical officerChief executive officerMedical affairs

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (3)

75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of.

United statesCarsten brunnAnders ullmanThomas kudsk larsenheadSelecta biosciencesGuido oelkersPeter traberPrnewswire selecta biosciences incSobi investor relations teamExchange commissionCompany immSelecta biosciences incHead of research developmentChief medical officerChief executive officerMedical affairs

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB

/PRNewswire/ Selecta Biosciences, Inc. (NASDAQ: SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo.

United statesCarsten brunnAnders ullmanBlaine davisSelecta biosciencesThomas kudsk larsenGuido oelkersPeter traberSobi investor relations teamExchange commissionCompany immSelecta biosciences incHead of research developmentChief medical officerChief executive officerMedical affairs

Selecta Biosciences (SELB) Reports Phase 3 DISSOLVE Program of SEL-212 Met Primary Endpoint

Selecta Biosciences (SELB) Reports Phase 3 DISSOLVE Program of SEL-212 Met Primary Endpoint
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCarsten brunnAnders ullmanThomas kudsk larsenheadSelecta biosciencesGuido oelkersPeter traberSobi investor relations teamExchange commissionCompany immSelecta biosciences incHead of research developmentChief medical officerChief executive officerMedical affairsConference call